Organization
Beijing Obstetrics and Gynecolgoy Hospital, Capital Medical University, Beijing, China
2 abstracts
Abstract
Fruquintinib plus sintilimab in treated advanced endometrial cancer (EMC) patients (pts) with PMMR status: Results from a multicenter, single-arm phase 2 study.Org: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Liaoning Cancer Hospital, Liaoning, China, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China, Department of Gynecologic Oncology, affiliated Cancer Hospital of Chonqing University, Chongqing, China, Beijing Obstetrics and Gynecolgoy Hospital, Capital Medical University, Beijing, China,
Abstract
A single-arm, multicenter, phase II study of utidelone in advanced solid tumors: Efficacy data from screening and the expansion cohort assessing utidelone plus sintilimab and oxaliplatin for advanced gastric cancer.Org: Peking University Shenzhen Hospital, Beijing Obstetrics and Gynecolgoy Hospital, Capital Medical University, Beijing, China, Beijing Biostar Pharmaceuticals,